Discovery and characterization of a novel candidate gene for inherited hearing loss
遗传性听力损失的新候选基因的发现和表征
基本信息
- 批准号:10228506
- 负责人:
- 金额:$ 3.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-16 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAffectAgeAldehyde-LyasesAldolase AAldolase CAllelesAuditoryAuditory Brainstem ResponsesBasic ScienceBilateralBiochemicalBiochemistryBiologicalBiological AssayBiological ModelsBiologyBrainCRISPR/Cas technologyCandidate Disease GeneCell DeathCell SurvivalCellsCellular MorphologyCellular biologyChildClinicalClinical DataCochleaCochlear ImplantsCommunicationComplementData ScienceDevelopmentDiagnosticDietEnzyme KineticsEnzymesEpithelialEquilibriumEscherichia coliEvaluationExperimental DesignsExposure toFamilyFructoseFutureGene MutationGenesGeneticGenetic EnhancementGenetic TranscriptionGenomicsGenotypeGlycolysisGoalsGrowthHair CellsHearingHearing AidsHereditary fructose intolerance syndromeHomozygoteHumanHybridsImmunohistochemistryIn VitroIndividualInternationalIsoenzymesKineticsLaboratoriesLabyrinthLeadLearningMammalsMeasuresMentorshipMetabolicMetabolismMiddle EastMissense MutationMolecularMorphologyMusMutateMutationNeurosciencesOrgan of CortiOtolaryngologyPhenotypePhysiciansPlayPopulationPrivatizationPropertyProteinsPublic HealthQuality of lifeRecording of previous eventsRecreationRoleScanning Electron MicroscopyScientistSensorySiblingsSupplementationTechniquesTemperatureTestingTimeTrainingTranslational ResearchUniversitiesVisitWashingtonWild Type Mousebasecareercell typeconsanguineous familydesigndietaryexomeexperienceexperimental studyfructose-1-phosphategene discoverygene functiongenetic disorder diagnosisgenetic testinggenome sequencinggenomic toolshearing impairmenthepatocyte injuryhereditary hearing lossin vitro Assayin vivoin vivo Modelinsightinterdisciplinary collaborationinterestmeltingmouse modelmutantneurodevelopmentnew therapeutic targetnovelnovel therapeuticsparalogous genepostnatalprotein functionresearch clinical testingrestorationscientific literacysingle-cell RNA sequencingsocialsuccesstargeted treatmenttherapy developmentthermostabilitytooltranscriptomicswhole genome
项目摘要
PROJECT SUMMARY/ABSTRACT
The goal of this proposal is to characterize a novel candidate gene for inherited hearing loss using clinical, genomic,
and biological tools. The approach combines clinical evaluation of informative families, genome sequencing to identify
candidate genes, in vitro analysis of the consequences of candidate mutant alleles on gene and protein function, and in
vivo recreation and full evaluation of the phenotype observed in CRISPR-Cas9 mice bearing the human candidate
genotype. The identification of new genes for hearing loss will expand diagnostic genetic testing, yield insight into cellular
and molecular mechanisms of hearing, and allow for future development of therapies targeting these mechanisms.
My proposal describes the application of this approach to a consanguineous family with two children with congenital,
bilateral, profound, non-syndromic hearing loss. The children are homozygous for the missense mutation ALDOC
p.R149C. ALDOC encodes aldolase C, one of three aldolase isozymes (A, B, and C) that are critical for glycolysis and
fructose metabolism. ALDOC is highly expressed in brain and in the sensory epithelium of the inner ear and plays a role
in neurodevelopment. Mutations in its paralog, ALDOB, lead to hereditary fructose intolerance where accumulation of
the substrate fructose-1-phosphate causes hepatocyte injury and cell death. Here, we propose a similar mechanism
within the inner ear for ALDOC-related hearing loss and outline experimental approaches to test this hypothesis.
Aim 1. To evaluate the biochemical properties of mutant ALDOC p.R149C, I first purified wild-type and mutated aldolase
C from E. coli and demonstrated near complete loss of catalytic activity of the mutant protein. To further quantify this
mutation’s effects, I will complete thermostability testing, Michael-Menten enzyme kinetics calculations, and also
evaluate its effect on aldolase heteromers by creating and assaying an aldolase A/C hybrid set.
Aim 2. To evaluate the phenotypic effects of Aldoc p.R149C, I designed a CRISPR-Cas9 mouse carrying the human
mutation. Preliminary results from homozygous mice show a mild hearing loss. Next, I will thoroughly evaluate the
hearing of the homozygotes, with and without fructose supplementation, by auditory brainstem response (ABR) testing
and analyze cochlear explants by immunohistochemistry and scanning electron microscopy.
Aim 3. To determine the cell type(s) involved in ALDOC p.R149C hearing loss, I will utilize single-cell RNA sequencing
to identify differences in inner ear cell populations between wild type and Aldoc p.R149C homozygous mice.
My project will provide training across auditory neuroscience, biochemistry, and genomics. It will afford ample
opportunities for growth in scientific literacy and communication, experimental design and execution, and
interdisciplinary collaboration. It is complemented by clinical exposure to otolaryngology and embedded in the UW
MSTP, which has 50 years’ experience training physician-scientists. This integrated training plan will provide the
experience and mentorship necessary to begin a successful career as a physician scientist.
项目概要/摘要
该提案的目标是利用临床、基因组、
该方法结合了信息丰富的家庭的临床评估、基因组测序来识别。
候选基因,候选突变等位基因对基因和蛋白质功能的影响的体外分析,以及
对携带人类候选者的 CRISPR-Cas9 小鼠中观察到的表型进行体内重建和全面评估
听力损失新基因的鉴定将扩大诊断基因测试,深入了解细胞。
和听力的分子机制,并允许未来开发针对这些机制的疗法。
我的提案描述了这种方法在有两个患有先天性、
双侧、深度、非综合征性听力损失 这些儿童是错义突变 ALDOC 的纯合子。
p.R149C 编码醛缩酶 C,它是对糖酵解至关重要的三种醛缩酶同工酶(A、B 和 C)之一。
ALDOC 在大脑和内耳感觉上皮中高度表达,并发挥作用。
其旁系同源物 ALDOB 的突变会导致遗传性果糖不耐受,其中积累
底物果糖-1-磷酸会导致肝细胞损伤和细胞死亡。在这里,我们提出了类似的机制。
内耳中与 ALDOC 相关的听力损失,并概述了检验这一假设的实验方法。
目的 1. 为了评估突变型 ALDOC p.R149C 的生化特性,我首先纯化了野生型和突变型醛缩酶
来自大肠杆菌的 C 并证明突变蛋白的催化活性几乎完全丧失,以进一步量化这一点。
突变的影响,我将完成热稳定性测试、Michael-Menten 酶动力学计算,以及
通过创建和测定醛缩酶 A/C 混合组来评估其对醛缩酶异聚体的影响。
目标 2. 为了评估 Aldoc p.R149C 的表型效应,我设计了一只携带人类基因的 CRISPR-Cas9 小鼠
纯合子小鼠的初步结果显示有轻微的听力损失,接下来我将彻底评估。
通过听觉脑干反应 (ABR) 测试,在补充或不补充果糖的情况下纯合子的听力
并通过免疫组织化学和扫描电子显微镜分析耳蜗外植体。
目标 3. 为了确定 ALDOC p.R149C 听力损失所涉及的细胞类型,我将利用单细胞 RNA 测序
鉴定野生型和 Aldoc p.R149C 纯合小鼠内耳细胞群的差异。
我的项目将提供听觉神经科学、生物化学和基因组学方面的培训。
科学素养和交流、实验设计和执行的增长机会,以及
它以耳鼻喉科的临床接触为补充,并嵌入华盛顿大学。
MSTP 拥有 50 年培训医师科学家的经验。该综合培训计划将提供以下服务:
作为一名医师科学家开始成功的职业生涯所必需的经验和指导。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ryan James Carlson其他文献
Ryan James Carlson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
- 批准号:82373667
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于年龄和空间的非随机混合对性传播感染影响的建模与研究
- 批准号:12301629
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
- 批准号:82304205
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
运动状态下代谢率的年龄变化特征及对人体热舒适的影响研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
基于堆叠式集成学习探索人居环境对生物学年龄的影响
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 3.99万 - 项目类别:
The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
- 批准号:
10748606 - 财政年份:2024
- 资助金额:
$ 3.99万 - 项目类别:
Early Life Stress Induced Reprogramming of Vascular Function by the Endothelium and Macrophage Systems
生命早期的压力诱导内皮细胞和巨噬细胞系统对血管功能进行重新编程
- 批准号:
10555125 - 财政年份:2023
- 资助金额:
$ 3.99万 - 项目类别:
Identifying and testing a tailored strategy to achieve equity in blood pressure control in PACT
确定并测试量身定制的策略,以在 PACT 中实现血压控制的公平性
- 批准号:
10538513 - 财政年份:2023
- 资助金额:
$ 3.99万 - 项目类别: